Intervacc AB (publ) (2E9.F)

0.3160 -0.0205 (-6.09%) As of 09:30AM CEST. Market open.

Intervacc AB (publ)

Västertorpsvägen 135
Hägersten 129 44
Sweden
46 8 12 01 06 00
https://www.intervacc.se

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 15

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jonas Sohlman	Chief Executive Officer	N/A	N/A	1965
Mr. Jan Persson	Chief Financial Officer	N/A	N/A	N/A
Mr. Patrik Hellberg	Chief Investment Officer	N/A	N/A	N/A
Dr. Andrew Waller	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. Its product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. The company also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. Intervacc AB (publ) was incorporated in 1983 and is based in Hägersten, Sweden.

Corporate Governance

Intervacc AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.